ASX - By Stock
|
MSB |
Re:
Let's just get this done at $10 per MSB share
|
|
yelrom
|
114 |
38K |
11 |
25/02/21 |
25/02/21 |
ASX - By Stock
|
114
|
38K
|
11
|
|
ASX - By Stock
|
MSB |
Re:
Let's just get this done at $10 per MSB share
|
|
yelrom
|
114 |
38K |
2 |
25/02/21 |
25/02/21 |
ASX - By Stock
|
114
|
38K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Mesoblast Pale Ale
|
|
yelrom
|
21 |
7.4K |
4 |
23/02/21 |
23/02/21 |
ASX - By Stock
|
21
|
7.4K
|
4
|
|
ASX - By Stock
|
MSB |
Re:
Mesoblast Partnership Announcements
|
|
yelrom
|
90 |
32K |
13 |
22/02/21 |
22/02/21 |
ASX - By Stock
|
90
|
32K
|
13
|
|
ASX - By Stock
|
MSB |
Re:
The Psychology of Trading
|
|
yelrom
|
905 |
286K |
21 |
21/02/21 |
21/02/21 |
ASX - By Stock
|
905
|
286K
|
21
|
|
ASX - By Stock
|
MSB |
Re:
Novartis - Heart Failure - Primary Endpoints
|
|
yelrom
|
100 |
27K |
17 |
19/02/21 |
19/02/21 |
ASX - By Stock
|
100
|
27K
|
17
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Phase 3 Chronic Low Back Pain Results
|
|
yelrom
|
1.1K |
313K |
21 |
18/02/21 |
18/02/21 |
ASX - By Stock
|
1.1K
|
313K
|
21
|
|
ASX - By Stock
|
MSB |
Re:
Self-Sustaining Commercialisation?
|
|
yelrom
|
175 |
41K |
16 |
17/02/21 |
17/02/21 |
ASX - By Stock
|
175
|
41K
|
16
|
|
ASX - By Stock
|
MSB |
Re:
MSB Video channel'
|
|
yelrom
|
56 |
20K |
11 |
16/02/21 |
16/02/21 |
ASX - By Stock
|
56
|
20K
|
11
|
|
ASX - By Stock
|
MSB |
Re:
Self-Sustaining Commercialisation?
|
|
yelrom
|
175 |
41K |
38 |
16/02/21 |
16/02/21 |
ASX - By Stock
|
175
|
41K
|
38
|
|
ASX - By Stock
|
MSB |
Re:
News Flash: 9 Analysts Think Mesoblast Limited (ASX:MSB) Earnings Are Under Threat
|
|
yelrom
|
230 |
57K |
18 |
16/02/21 |
16/02/21 |
ASX - By Stock
|
230
|
57K
|
18
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading 2021 - paradigm shift
|
|
yelrom
|
10K |
3.0M |
4 |
16/02/21 |
16/02/21 |
ASX - By Stock
|
10K
|
3.0M
|
4
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading 2021 - paradigm shift
|
|
yelrom
|
10K |
3.0M |
16 |
15/02/21 |
15/02/21 |
ASX - By Stock
|
10K
|
3.0M
|
16
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading 2021 - paradigm shift
|
|
yelrom
|
10K |
3.0M |
1 |
13/02/21 |
13/02/21 |
ASX - By Stock
|
10K
|
3.0M
|
1
|
|
ASX - By Stock
|
MSB |
Re:
The Psychology of Trading
|
|
yelrom
|
905 |
286K |
18 |
12/02/21 |
12/02/21 |
ASX - By Stock
|
905
|
286K
|
18
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Phase 3 Chronic Low Back Pain Results
|
|
yelrom
|
1.1K |
313K |
17 |
12/02/21 |
12/02/21 |
ASX - By Stock
|
1.1K
|
313K
|
17
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Phase 3 Chronic Low Back Pain Results
|
|
yelrom
|
1.1K |
313K |
1 |
12/02/21 |
12/02/21 |
ASX - By Stock
|
1.1K
|
313K
|
1
|
|
ASX - By Stock
|
MSB |
Re:
MESO Nasdaq update
|
|
yelrom
|
5.4K |
2.6M |
7 |
12/02/21 |
12/02/21 |
ASX - By Stock
|
5.4K
|
2.6M
|
7
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Phase 3 Chronic Low Back Pain Results
|
|
yelrom
|
1.1K |
313K |
11 |
11/02/21 |
11/02/21 |
ASX - By Stock
|
1.1K
|
313K
|
11
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Phase 3 Chronic Low Back Pain Results
|
|
yelrom
|
1.1K |
313K |
21 |
11/02/21 |
11/02/21 |
ASX - By Stock
|
1.1K
|
313K
|
21
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Phase 3 Chronic Low Back Pain Results
|
|
yelrom
|
1.1K |
313K |
14 |
11/02/21 |
11/02/21 |
ASX - By Stock
|
1.1K
|
313K
|
14
|
|
ASX - By Stock
|
MSB |
Re:
MPC-06-ID Phase 3 results countdown
|
|
yelrom
|
273 |
141K |
23 |
09/02/21 |
09/02/21 |
ASX - By Stock
|
273
|
141K
|
23
|
|
ASX - By Stock
|
MSB |
Re:
Funding MSB
|
|
yelrom
|
72 |
20K |
18 |
07/02/21 |
07/02/21 |
ASX - By Stock
|
72
|
20K
|
18
|
|
ASX - By Stock
|
MSB |
Re:
The Psychology of Trading
|
|
yelrom
|
905 |
286K |
40 |
05/02/21 |
05/02/21 |
ASX - By Stock
|
905
|
286K
|
40
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading 2021 - paradigm shift
|
|
yelrom
|
10K |
3.0M |
28 |
03/02/21 |
03/02/21 |
ASX - By Stock
|
10K
|
3.0M
|
28
|
|
ASX - By Stock
|
MSB |
Re:
Short position- MSB 3rd most heavily shorted ASX o share
|
|
yelrom
|
29 |
12K |
16 |
02/02/21 |
02/02/21 |
ASX - By Stock
|
29
|
12K
|
16
|
|
ASX - By Stock
|
MSB |
Re:
MSB Short Position Reporting
|
|
yelrom
|
255 |
83K |
13 |
28/01/21 |
28/01/21 |
ASX - By Stock
|
255
|
83K
|
13
|
|
ASX - By Stock
|
MSB |
Re:
MSB to dispute FDA finding in Type A meeting
|
|
yelrom
|
1.0K |
502K |
35 |
18/01/21 |
18/01/21 |
ASX - By Stock
|
1.0K
|
502K
|
35
|
|
ASX - By Stock
|
MSB |
Re:
MSB to dispute FDA finding in Type A meeting
|
|
yelrom
|
1.0K |
502K |
31 |
16/01/21 |
16/01/21 |
ASX - By Stock
|
1.0K
|
502K
|
31
|
|
ASX - By Stock
|
MSB |
Re:
MSB Short Position Reporting
|
|
yelrom
|
255 |
83K |
18 |
13/01/21 |
13/01/21 |
ASX - By Stock
|
255
|
83K
|
18
|
|
ASX - By Stock
|
MSB |
Re:
MSB Short Position Reporting
|
|
yelrom
|
255 |
83K |
29 |
12/01/21 |
12/01/21 |
ASX - By Stock
|
255
|
83K
|
29
|
|
ASX - By Stock
|
MSB |
Re:
The Psychology of Trading
|
|
yelrom
|
905 |
286K |
7 |
12/01/21 |
12/01/21 |
ASX - By Stock
|
905
|
286K
|
7
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading 2021 - paradigm shift
|
|
yelrom
|
10K |
3.0M |
27 |
11/01/21 |
11/01/21 |
ASX - By Stock
|
10K
|
3.0M
|
27
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Rexlemestrocel Reduces Heart Attacks/Strokes/CV Death in CHF
|
|
yelrom
|
763 |
324K |
8 |
11/01/21 |
11/01/21 |
ASX - By Stock
|
763
|
324K
|
8
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading 2021 - paradigm shift
|
|
yelrom
|
10K |
3.0M |
17 |
11/01/21 |
11/01/21 |
ASX - By Stock
|
10K
|
3.0M
|
17
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Rexlemestrocel Reduces Heart Attacks/Strokes/CV Death in CHF
|
|
yelrom
|
763 |
324K |
19 |
11/01/21 |
11/01/21 |
ASX - By Stock
|
763
|
324K
|
19
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading 2021 - paradigm shift
|
|
yelrom
|
10K |
3.0M |
8 |
11/01/21 |
11/01/21 |
ASX - By Stock
|
10K
|
3.0M
|
8
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Rexlemestrocel Reduces Heart Attacks/Strokes/CV Death in CHF
|
|
yelrom
|
763 |
324K |
3 |
11/01/21 |
11/01/21 |
ASX - By Stock
|
763
|
324K
|
3
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Rexlemestrocel Reduces Heart Attacks/Strokes/CV Death in CHF
|
|
yelrom
|
763 |
324K |
40 |
11/01/21 |
11/01/21 |
ASX - By Stock
|
763
|
324K
|
40
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading 2021 - paradigm shift
|
|
yelrom
|
10K |
3.0M |
7 |
11/01/21 |
11/01/21 |
ASX - By Stock
|
10K
|
3.0M
|
7
|
|
ASX - By Stock
|
MSB |
Re:
Red Red Whine
|
|
yelrom
|
58 |
20K |
5 |
10/01/21 |
10/01/21 |
ASX - By Stock
|
58
|
20K
|
5
|
|
ASX - By Stock
|
MSB |
Re:
COVID-19 USA Daily Numbers
|
|
yelrom
|
675 |
193K |
17 |
10/01/21 |
10/01/21 |
ASX - By Stock
|
675
|
193K
|
17
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading 2021 - paradigm shift
|
|
yelrom
|
10K |
3.0M |
8 |
10/01/21 |
10/01/21 |
ASX - By Stock
|
10K
|
3.0M
|
8
|
|
ASX - By Stock
|
MSB |
Re:
USD573M in retained losses and a less than great 2020!. 2021 a year that cannot get worse
|
|
yelrom
|
311 |
91K |
14 |
09/01/21 |
09/01/21 |
ASX - By Stock
|
311
|
91K
|
14
|
|
ASX - By Stock
|
MSB |
Re:
USD573M in retained losses and a less than great 2020!. 2021 a year that cannot get worse
|
|
yelrom
|
311 |
91K |
7 |
09/01/21 |
09/01/21 |
ASX - By Stock
|
311
|
91K
|
7
|
|
ASX - By Stock
|
MSB |
Re:
MSB CR
|
|
yelrom
|
11 |
3.8K |
9 |
08/01/21 |
08/01/21 |
ASX - By Stock
|
11
|
3.8K
|
9
|
|
ASX - By Stock
|
MSB |
Re:
USD573M in retained losses and a less than great 2020!. 2021 a year that cannot get worse
|
|
yelrom
|
311 |
91K |
14 |
08/01/21 |
08/01/21 |
ASX - By Stock
|
311
|
91K
|
14
|
|
ASX - By Stock
|
MSB |
Re:
USD573M in retained losses and a less than great 2020!. 2021 a year that cannot get worse
|
|
yelrom
|
311 |
91K |
5 |
08/01/21 |
08/01/21 |
ASX - By Stock
|
311
|
91K
|
5
|
|
ASX - By Stock
|
MSB |
Re:
USD573M in retained losses and a less than great 2020!. 2021 a year that cannot get worse
|
|
yelrom
|
311 |
91K |
19 |
08/01/21 |
08/01/21 |
ASX - By Stock
|
311
|
91K
|
19
|
|
ASX - By Stock
|
MSB |
Re:
USD573M in retained losses and a less than great 2020!. 2021 a year that cannot get worse
|
|
yelrom
|
311 |
91K |
7 |
08/01/21 |
08/01/21 |
ASX - By Stock
|
311
|
91K
|
7
|
|